Wednesday, 13 May 2026 05:20 PM
Company Update
A look back on the first year of Bioscope.ai
CARMEL, IN / ACCESS Newswire / May 13, 2026 / Bioscope.ai is the clinical AI platform built for precision longevity medicine. In its first year of operations, the company has assembled a team of more than 40 professionals spanning medicine, science, artificial intelligence and engineering, attracted active physician users to the platform and established the foundational infrastructure for a new model of preventive care.
A Year of Meaningful Progress
Since its incorporation in May 2025, Bioscope.ai has built a functioning clinical product, launched the Bioscope Foundry to enable physicians to practice medicine the way they want, and formed medical, scientific, and patient advisory boards to guide Bioscope.ai's clinical direction.
The company has presented its work at several leading medical conferences, drawing standing-room audiences, and continues to expand its physician user base across the United States.
"When I incorporated Bioscope one year ago today, I recognized that artificial intelligence had matured to a point where precision longevity physicians could finally practice medicine the way they had always intended to," said Dr. Donald E. Brown, Founder and CEO of Bioscope.ai. "Beyond access to data, omics results, and patient records, we could now deliver tools that translate that information into genuine clinical insight. This is the fifth company I have founded, and I have never been more energized by the work. I am proud of what this team has accomplished in our first year, and we are only at the beginning."
First Year Accomplishments:
Built and released the full Bioscope.ai product platform, subsequently expanding it to include a multidimensional health dashboard, an AI-powered clinical query function, a conversational patient intake system, a longitudinal medical history timeline, and whole genome analysis at the clinical level.
Integrated Scite, providing physicians with direct access to more than one million peer-reviewed biomedical publications from within the clinical interface.
More than 50 physicians have evaluated the product firsthand.
Several practices have adopted the Bioscope.ai platform and are already using it to manage patient care.
Launched Bioscope Foundry to empower physicians to practice medicine the way they want by seamlessly launching their own practice.
Formed medical, scientific, and patient advisory boards.
Grown from a founding team of one to more than 40 employees, including senior medical professionals, research scientists, and AI specialists.
Launched end-to-end microbiome testing, covering kit ordering, patient survey, dedicated results page, and full platform integration.
Deployed EMR integrations with Elation and Cerbo, with Athena in progress.
Introduced polygenic risk score (PRS) displays with a clinical context and clearer risk stratification.
Launched Longevity Today, a curated research platform paired with an AI longevity team, designed for patients and longevity enthusiasts.
Looking Ahead
In its second year, Bioscope.ai will continue expanding its clinical capabilities, deepening its physician network, and advancing the case that preventive, data-informed medicine is both scientifically sound and operationally practical for modern medical practices.
Bioscope.ai is a pioneer in clinical AI-powered medicine solutions. The company leverages artificial intelligence, genomics, and advanced diagnostics to help physicians prevent disease rather than simply treat it. When disease does occur, Bioscope enables earlier detection and clearer clinical insight, empowering physicians to help patients live longer, healthier lives. To learn more, visit www.bioscope.ai
Press inquiries contact Joe Staples - [email protected]
SOURCE: Bioscope.ai